Drug Profile
CN 105
Alternative Names: Ac-VSRRR-NH2; CN-105Latest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator CereNova; Duke University
- Developer AegisCN; Beijing Tian Tan Hospital; Duke University
- Class Anti-inflammatories; Antihaemorrhagics; Apolipoprotein therapeutics; Behavioural disorder therapies; Neuropeptides; Neuroprotectants; Nootropics; Peptides; Small molecules
- Mechanism of Action Apolipoprotein E agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cerebral haemorrhage; Cognition disorders; Delirium
Most Recent Events
- 15 Feb 2022 No development reported - Phase-II for Cerebral haemorrhage in USA (IV)
- 30 Jun 2019 AegisCN completes a phase II trial in Cerebral haemorrhage in USA (NCT03168581)
- 26 Oct 2018 Aegis CN in collaboration with National Neuroscience Institute plans the phase II S-CATCH trial in Cerebral haemorrhage in November 2018 (NCT03711903)